Amica Mutual Insurance Co. Has $4.17 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Amica Mutual Insurance Co. increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 44.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 157,064 shares of the biopharmaceutical company's stock after purchasing an additional 48,541 shares during the period. Amica Mutual Insurance Co.'s holdings in Pfizer were worth $4,167,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nordea Investment Management AB raised its position in shares of Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI boosted its holdings in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after acquiring an additional 159,984 shares during the period. NFJ Investment Group LLC grew its position in shares of Pfizer by 12.8% during the third quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after acquiring an additional 43,719 shares during the last quarter. Copley Financial Group Inc. acquired a new stake in shares of Pfizer in the 3rd quarter worth about $577,000. Finally, Zacks Investment Management lifted its position in Pfizer by 10.9% in the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock valued at $69,142,000 after purchasing an additional 235,243 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PFE shares. Bank of America restated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Stock Up 0.8 %

Shares of PFE traded up $0.19 during mid-day trading on Friday, reaching $25.20. The company's stock had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The company has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a fifty day moving average of $26.06 and a 200 day moving average of $26.92.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.